The European Commission (EC) has approved sugemalimab (brand name: Cejemly®) in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback